A Study Comparing Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH).
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
This study will examine the efficacy and safety of Xalacom comparing with those of Xalatan in
Japanese patients with POAG or OH, in order to show superiority of Xalacom over Xalatan in
efficacy and similarity of safety between Xalacom and Xalatan.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.